{'fraction_non_alphanumeric': 0.02631578947368421, 'fraction_numerical': 0.012145748987854251, 'mean_word_length': 4.922155688622754, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effects of calcifediol on calcified tissue in uremia.

Disorders in the synthesis of the active metabolites of vitamin D, 1,2 dialysate calcium (Ca) concentration, 3 dietary Ca and phosphorus (P), 4 and secondary hyperparathyroidism 5 have been shown to influence Ca metabolism and the severity of the bone disease associated with uremia. The present study was designed to evaluate the effects of pharmacologic doses of calcifediol (25-hydroxy vitamin D 3 , [25OHD 3 ]) on total body Ca (TBCa) and the bone mineral content (BMC) of the distal radius in patients with uremia. Previous studies from our laboratory have indicated that the serial and simultaneous measurements of TBCa and BMC of the distal radius reflect long-term changes in Ca balance and calcified tissue mass, as well as the distribution of Ca between bone and soft tissue. 6 Since calcifediol influences the absorption and distribution of Ca, as well as has a direct effect on bone collagen metabolism in uremic animals,